Last reviewed · How we verify
Cocaine N-acetylcysteine
N-acetylcysteine replenishes glutathione stores and provides antioxidant protection to counteract cocaine-induced oxidative stress and toxicity.
N-acetylcysteine replenishes glutathione stores and provides antioxidant protection to counteract cocaine-induced oxidative stress and toxicity. Used for Cocaine use disorder and cocaine toxicity mitigation.
At a glance
| Generic name | Cocaine N-acetylcysteine |
|---|---|
| Also known as | NAC |
| Sponsor | Hospital de Clinicas de Porto Alegre |
| Drug class | Antioxidant / Glutathione precursor |
| Target | Glutathione synthesis pathway; indirect antioxidant effects |
| Modality | Small molecule |
| Therapeutic area | Addiction Medicine / Toxicology |
| Phase | FDA-approved |
Mechanism of action
Cocaine causes acute oxidative stress and depletion of the antioxidant glutathione in tissues, particularly in the brain and cardiovascular system. N-acetylcysteine (NAC) is a glutathione precursor that restores cellular antioxidant capacity and reduces reactive oxygen species, thereby mitigating cocaine-related cellular damage and potentially reducing addiction-related neurobiological changes.
Approved indications
- Cocaine use disorder and cocaine toxicity mitigation
Common side effects
- Nausea
- Headache
- Rash
Key clinical trials
- Behavioral Effects of Drugs (Inpatient): 43 (Opioids, Cocaine, n-Acetylcysteine) (EARLY_PHASE1)
- Neurocircuit Strategy to Decrease Cocaine Cue Reactivity (PHASE2)
- Airway Stents for Excessive Dynamic Airway Collapse (NA)
- Efficacy of N-acetylcysteine on the Craving Symptoms of Abstinent Hospitalized Patients With Cocaine Addiction (PHASE2)
- Mechanisms of N-acetylcysteine Mediated Vascular Adverse Effects (NA)
- Glutamate-Glutamine Cycling (VCYC) During Cocaine Abstinence Using 1H-MRS (PHASE1)
- Functional Magnetic Resonance Imaging of N-acetylcysteine in Cocaine Dependence (EARLY_PHASE1)
- Evaluation of N-Acetylcysteine Efficacy to Reduce the Craving and to Prolong Abstinence Time of Coca Paste (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cocaine N-acetylcysteine CI brief — competitive landscape report
- Cocaine N-acetylcysteine updates RSS · CI watch RSS
- Hospital de Clinicas de Porto Alegre portfolio CI